Growth Metrics

Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2025)

Historic Gross Profit for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to $257.0 million.

  • Acadia Pharmaceuticals' Gross Profit rose 1098.8% to $257.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $962.5 million, marking a year-over-year increase of 1306.64%. This contributed to the annual value of $876.0 million for FY2024, which is 2791.43% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Gross Profit is $257.0 million, which was up 1098.8% from $243.8 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Gross Profit peaked at $257.0 million during Q3 2025, and registered a low of $104.4 million during Q1 2021.
  • In the last 5 years, Acadia Pharmaceuticals' Gross Profit had a median value of $157.8 million in 2023 and averaged $171.5 million.
  • Its Gross Profit has fluctuated over the past 5 years, first skyrocketed by 51.12% in 2022, then skyrocketed by 5897.58% in 2023.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Gross Profit stood at $120.0 million in 2021, then increased by 11.72% to $134.1 million in 2022, then soared by 58.98% to $213.2 million in 2023, then increased by 11.56% to $237.8 million in 2024, then grew by 8.07% to $257.0 million in 2025.
  • Its Gross Profit was $257.0 million in Q3 2025, compared to $243.8 million in Q2 2025 and $223.9 million in Q1 2025.